Those who are still undecided regarding the potential of...

Those who are still undecided regarding the potential of artimist may be interested in reading an extract from HC Berlin Pharma AG Investor Relations of which EMS holds around 18% of the listed shares. When results are released could be commercialized quite quickly once regulatory approval has been given. What I particularly like is the last paragraph.

In regards to the delay in announcement. Get real! A half baked announcement saying there is a delay is stating the obvious. I would prefer the real deal.If you believe in the product and have done your research holding a few more weeks should not be a problem.


Market potential

ArTiMist
For Malaria treatment the market possibilities are enormous for the offered product. Malaria with more than 500 million new infection cases worldwide each year is one of the most important diseases with no market saturation. The marketing strategy of HC Berlin Pharma AG concentrates on important Aid Organizations like Bill & Melinda Gates Foundation, Kenneth Kaunda Foundation Safe the Children, etc. as well as national and supranational organizations like WHO, Red Cross, etc. All these organizations have the problem that mainly the Malaria infected children more than 50 % of all registered Malaria cases cannot absorb the usual treatments (tablets etc.) due to malnutrition and diarrhea. The sublingual spray ArTiMist can be administered to the child even by family members, hospital or medical doctor presence is not necessary for successful treatment.

Furthermore, the costs of ArTiMist are much lower than those of the medicines in tablet form offered by our competitors, giving us an additional competitive edge.

The market potential for Malaria treatments based on Artemisinin has been estimated by WHO already in 2005 for 220 million treatments; but it could only supply 30 million treatments during 2005. HC Berlin Pharma AG plans to cover part of this supply deficit with the new treatment ArTiMist with about 10 million treatments every year, which is 5 % of the annual demand of production capacity of 10 million treatments.

NiCoSorb
For the nicotine replacement the global market situation is similar. NiCoSorb covers in the market the segment Life-Style-Medicine. About 15 billion cigarettes are sold worldwide daily, experts judge the number of new smokers in youth age with about 100,000 each day. These figures characterize the high Nicotine dependence. With smoking in public places banned in many countries smokers have a problem.

NiCoSorb as an innovative nicotine replacement can give assistance to this persons at most competitive cost. After utilization the nicotine demand of the human body is satisfied under one minute, without impairing the body and the surroundings, and a targeted reduction of the Nicotine consumption is possible.

Exclusive contracts with Eastland Medical Systems Ltd. have meanwhile secured the exclusive production and distribution rights for the nicotine replacement for HC Berlin Pharma AG.


Worldwide networking strong support from decision makers
HC Berlin Pharma's commitment and product developments are particularly geared towards the difficult treatment of children suffering from malaria. The top decision makers in African healthcare policies support HC Berlin Pharma AG. The patron of the initiative to fight malaria is Dr Kenneth Kaunda, the first president of the Republic of Zambia.

Great importance is attached to the co-operation with the Nelson Mandela Foundation, which is expressed by the appointment of Nelson Mandela's son-in-law, Dr. I. K. Amuha, to the Supervisory Board of HC Berlin Pharma AG.

Groe Bedeutung wird auch der Zusammenarbeit mit der Nelson Mandela Foundation beigemessen, die durch die Berufung von Nelson Mandelas Schwiegersohn, Dr. I. K. Amuah, in den Aufsichtsrat der HC Berlin Pharma AG zum Ausdruck kommt.

At the same time, the company's CEO, Ottmar W. Geiger, has many years of experience in directing various development aid products in South-East Asia. Furthermore, the supervisory board of HC Berlin Pharma AG is made up of internationally renowned figures who have a dense international network in the pharmaceuticals industry and close contact to important decision makers, particularly on the African continent.

The company has selected Potsdam as its production location as it is an important part of Berlin/Brandenburg, an excellent region for scientific activities due its infrastructure for medical technology and its universities. This decision was also positively influenced by the full support given by the government of the federal state and the municipal authorities.

In the field of research and development the company is supported by the knowledge and skills of its own scientists and experts as well as those of our partners and of the universities. The distribution channels of these partners and international aid organisations are used to promote sales.


Optimal utilisation of resources
These synergies result in the highly efficient utilisation of internal expertise and resources. They enable the company to independently bring new drugs and medicines through all phases in the development of an active agent. In addition, HC Berlin Pharma AG has created a network of recognised scientists, clinical researchers and industrial experts in order to ensure an optimal selection of products and an optimal development strategy.

In the overall biotech development and value chain HC Berlin Pharma AG's business model concentrates on a segment that allows a steep rise in value with comparatively predictable costs and very limited risk.